Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 4,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Not applicable Interventional Results available

Erwinia Asparaginase After Allergy to PEG-Asparaginase in Treating Young Patients With Acute Lymphoblastic Leukemia

NCT00537030
View directory record Official record
Conditions
Adult Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
Interventions
Asparaginase, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Downey, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 22, 2026, 1:02 AM EDT
Withdrawn Phase 2 Interventional

A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma

NCT02794519
View directory record Official record
Conditions
Asthma
Interventions
Sirukumab, Placebo, Rescue medication
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
5
States / cities
Long Beach, California • Aventura, Florida • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mountain Cedar in Subjects 12 Years and Older

NCT01010971
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Ciclesonide HFA 160 μg, Ciclesonide HFA 80 μg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

NCT06977581
View directory record Official record
Conditions
Asthma
Interventions
PF-07275315, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Mobile, Alabama • Chandler, Arizona • Lancaster, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Informed Consent Formats by Information Preference and Priority

NCT03416907
View directory record Official record
Conditions
Consent Forms, Asthma
Interventions
Original consent form, Shortened consent form, Reordered, shortened consent form, Shortened consent form with a highlights box, Interactive, shortened consent form
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional

Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics

NCT03215836
View directory record Official record
Conditions
Asthma, Obesity, Metabolic Syndrome
Interventions
Bronchoscopy and Nasal Epithelium Brush Sampling
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 2 Interventional

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

NCT00666172
View directory record Official record
Conditions
Atherosclerosis, Diabetes Mellitus, Obesity, Dyslipidemia, Hypertension
Interventions
Exercise, Weight Loss
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 22, 2026, 1:02 AM EDT
Active, not recruiting Phase 3 Interventional

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

NCT07003919
View directory record Official record
Conditions
Allergy, Peanut Allergy
Interventions
DBV712 250 mcg, Placebo
Combination Product
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
56
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Not yet recruiting No phase listed Observational

Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis

NCT06994130
View directory record Official record
Conditions
Hepatic Cancer
Interventions
Seravue
Diagnostic Test
Lead sponsor
ImCare Biotech
Industry
Eligibility
21 Years to 84 Years
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action

NCT00118729
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
GW685698X Aqueous Nasal Spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Woodstock, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 22, 2026, 1:02 AM EDT
Completed No phase listed Observational

Mechanisms of Allergen Immunotherapy

NCT00001910
View directory record Official record
Conditions
Asthma, Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting No phase listed Observational

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

NCT07645820
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nevisense electrical impedance spectroscopy
Device
Lead sponsor
Castle Biosciences Incorporated
Industry
Eligibility
12 Years to 89 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Rockville, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estradiol Effects on Alcohol Across the Menstrual Cycle

NCT04595682
View directory record Official record
Conditions
Alcohol Use, Unspecified
Interventions
Placebo, Alcohol
Drug
Lead sponsor
Mark Fillmore
Other
Eligibility
21 Years to 35 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Effectiveness of Telepsychiatry-based Culturally Sensitive Collaborative Treatment of Depressed Chinese Americans

NCT00854542
View directory record Official record
Conditions
Depression
Interventions
Telepsychiatry-based Culturally Sensitive Collaborative Treatment
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test

NCT03522675
View directory record Official record
Conditions
Allergy Skin, Allergy, Dermatitis, Allergic Contact
Interventions
NeoMatriX Wound MatriX Collagen Dressing
Device
Lead sponsor
NeXtGen Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

NCT05398445
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial

NCT01781637
View directory record Official record
Conditions
Peanut Allergy, Food Allergy
Interventions
Omalizumab, placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
7 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
4
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT06096857
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Roseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Personalized Approach To Habits - Sleep

NCT07029919
View directory record Official record
Conditions
Adolescent Behavior, Sleep Disturbance, Asthma in Children, Knowledge, Attitudes, Practice, Attitude, Habits
Interventions
PATH-S app
Behavioral
Lead sponsor
KDH Research & Communication
Industry
Eligibility
14 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Not listed Phase 4 Interventional

Comparative Study of Sinol and Sinol-M in Patients With Congestion Due to Allergic Rhinitis

NCT00825656
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Sinol or Sinol-M nasal spray
Drug
Lead sponsor
Strategic Biosciences
Industry
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2009 · Synced Oct 22, 2026, 1:02 AM EDT
Active, not recruiting No phase listed Observational

A Prognostic Transcriptomic Signature for Chronic Hypersensitivity Pneumonitis

NCT04844359
View directory record Official record
Conditions
Hypersensitivity Pneumonitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Tucson, Arizona • Sacramento, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Not listed Not applicable Interventional

Impact of Acute Exercise on Vascular Insulin Sensitivity in Metabolic Syndrome

NCT03894527
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Single Bout of Exercise, Control Condition
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 22, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

NCT00939094
View directory record Official record
Conditions
Neuropathic Pain, Mechanical Hypersensitivity
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2012 · Synced Oct 22, 2026, 1:02 AM EDT